他汀治疗及剂量与小腹主动脉瘤临床病程的关联:两项人群筛查试验的5年前瞻性队列研究
该研究纳入两项丹麦人群筛查试验中筛查发现的30-55 mm小腹主动脉瘤男性共998例,中位年龄69.5岁、中位瘤径35.4 mm,利用全国注册数据库量化他汀暴露。结果显示他汀每日每增加1个限定日剂量(DDD)与生长率调整变化-0.22 mm/年相关,他汀剂量每翻倍与修复风险(HR 0.82)及修复、破裂、死亡复合终点风险(HR 0.83)降低相关。
要点
- 他汀每日每增1 DDD与腹主动脉瘤生长率降低0.22 mm/年相关。
- 他汀剂量每翻倍,5年修复风险调整HR为0.82。
- 他汀剂量每翻倍,修复、破裂、死亡复合终点调整HR为0.83。
核心结论
- 高剂量他汀使用与腹主动脉瘤生长率降低及修复、破裂、死亡风险降低相关。
- 这项非随机研究提示腹主动脉瘤患者可能从高剂量他汀使用中获益,而不仅限于针对相关危险因素。
研究设计与样本
- 研究类型为前瞻性队列研究,数据来自Viborg血管筛查试验(纳入2008-2011年)和丹麦心血管筛查试验(纳入2014-2018年)两项大型人群随机筛查试验。
- 研究对象为两项筛查试验中筛查发现的30-55 mm腹主动脉瘤男性,共998例,中位年龄69.5岁(IQR 67-72),中位腹主动脉瘤直径35.4 mm(IQR 32-41.2)。
- 他汀暴露通过限定日剂量(DDD)量化,临床数据库补充了丹麦全国医疗注册库的处方与结局数据。
- 主要结局为腹主动脉瘤生长率,采用线性回归计算;次要结局包括需要修复以及修复、破裂和全因死亡的复合终点。
主要发现
- 他汀每日每增加1 DDD与生长率调整变化-0.22 mm/年相关(95%CI -0.39至-0.06;P=0.009)。
- 他汀剂量每翻倍,5年修复调整HR为0.82(95%CI 0.70-0.97;P=0.023),2.5年后显著。
- 他汀剂量每翻倍,修复、破裂、死亡复合终点调整HR为0.83(95%CI 0.73-0.94;P=0.003),呈剂量依赖性。
- 多种敏感性分析结果稳健。
临床怎么用
- 对于筛查发现的小腹主动脉瘤男性患者,可考虑使用高剂量他汀以延缓瘤体生长并降低修复、破裂和死亡风险。
- 他汀治疗决策应结合患者整体心血管风险,而不仅针对腹主动脉瘤相关危险因素。
局限性
- 本研究为非随机设计,不能确立因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Abdominal aortic aneurysms (AAA) present with high morbidity and mortality when they occasionally rupture. No medical therapy has successfully been proven to reduce AAA growth, though both metformin and statins have been identified as potential treatments in multiple meta-analysis. This study aimed to investigate a potential relationship between statin use and AAA growth rates and risk of undergoing repair, rupture, or death. METHODS: The study population included all men with screening-detected AAAs (30-55 mm) from the 2 large, population-based, randomized screening trials; the Viborg Vascular Screening trial (inclusion, 2008-2011) and the Danish Cardiovascular Screening trial (inclusion, 2014-2018). The clinical database was supplemented with data from the nationwide Danish Healthcare Registries, including prescription and outcome data. Statin exposure was quantified by defined daily doses (DDD). The primary outcome was AAA growth rate, whereas secondary outcomes included the need for repair and a composite of repair, rupture, and all-cause death. Growth rates were calculated using linear regression. To evaluate the risk of repair, patients were followed from inclusion until surgery, rupture, death, 5-year follow-up, or December 31, 2021. RESULTS: A total of 998 aneurysmal men (median age, 69.5 [interquartile range (IQR), 67-72] years; median AAA diameter, 35.4 [IQR, 32-41.2] mm) were included. Statin use was significantly associated with reduced AAA growth rate; an increase of 1 DDD statin per day was associated with an adjusted change in growth rate of -0.22 mm/year [95% CI, -0.39 to -0.06]; P=0.009). The 5-year adjusted hazard ratio for undergoing repair per doubling of statin dose presented a significantly reduced adjusted hazard ratio (HR) of 0.82 ([95% CI, 0.70-0.97]; P=0.023), which was significant after 2.5 years. Statin use was associated with a significantly lower risk of the composite outcome (surgery, rupture, and death) in a dose-dependent manner, with an adjusted HR of 0.83 ([95% CI, 0.73-0.94]; P=0.003) per doubling of statin dose. Findings were robust in a variety of sensitivity analyses. CONCLUSIONS: High-dose statin use was associated with decreased AAA growth rates and lowered risk of undergoing repair, rupture, and death. This nonrandomized study suggests that patients with AAA could benefit from high-dose statin use, beyond only targeting associated risk factors.
引用
- Skovbo JS, Obel LM, Diederichsen ACP, et al. Association of Statin Treatment and Dose With the Clinical Course of Small Abdominal Aortic Aneurysms in Men: A 5-Year Prospective Cohort Study From 2 Population-Based Screening Trials. Circulation. 2025. PMID: 40631665. doi:10.1161/CIRCULATIONAHA.125.074544
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。